Kidney oncocytoma

disease
On this page

Also known as kidney oncocytic neoplasmoncocytoma kidneyoncocytoma of kidneyoncocytoma of the kidneyoncocytoma renalrenal epithelial oncocytic neoplasmrenal epithelial oncocytic tumorrenal epithelial oncocytic tumourrenal oncocytomaROCY

Summary

Kidney oncocytoma (MONDO:0003825) is a disease and 3 clinical trials. Top therapeutic interventions include pazopanib hydrochloride. A subtype of kidney benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namekidney oncocytoma
Mondo IDMONDO:0003825
MeSHC537750
DOIDDOID:6245
NCITC4526
SNOMED CT254922006
UMLSC0346255
MedGen91094
Anatomy (UBERON)UBERON:0002113
Is cancer (heuristic)no

Also known as: kidney oncocytic neoplasm · kidney oncocytoma · oncocytoma kidney · oncocytoma of kidney · oncocytoma of the kidney · oncocytoma renal · renal epithelial oncocytic neoplasm · renal epithelial oncocytic tumor · renal epithelial oncocytic tumour · renal oncocytoma · ROCY

Disease family

This is a subtype of kidney benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmbenign neoplasmbenign urinary system neoplasmkidney benign neoplasmkidney oncocytoma

Related subtypes (11): kidney lipoma, benign cystic nephroma, renal adenoma, nephrogenic adenofibroma, nephrogenic adenoma, kidney angiomyolipoma, renal leiomyoma, benign metanephric tumor, benign neoplasm of renal pelvis, benign mesonephroma, nephroma

Subtypes (1): hereditary kidney oncocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified2
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01767636PHASE2COMPLETEDPazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
NCT06339138Not specifiedACTIVE_NOT_RECRUITINGIdentification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
NCT00898365Not specifiedCOMPLETEDStudy of Kidney Tumors in Younger Patients

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PAZOPANIB HYDROCHLORIDE41